A carregar...

More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes

Myelodysplastic syndromes (MDS) encompass a diverse group of hematologic disorders characterized by ineffective and malignant hematopoiesis, peripheral cytopenias and significantly increased risk of progression to acute myeloid leukemia (AML). The hypomethylating agents (HMA) azacitidine and decitab...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Hematol
Main Authors: Shallis, Rory M., Zeidan, Amer M.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5796398/
https://ncbi.nlm.nih.gov/pubmed/29435332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12878-018-0095-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!